Preexisting immune‐mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibitors

BACKGROUND: Immune‐related adverse events (irAEs) are common, clinically significant autoinflammatory toxicities observed with immune checkpoint inhibitors (ICI). Preexisting immune‐mediated inflammatory disease (pre‐IMID) is considered a relative contraindication to ICI due to the risk of inciting...

Descripción completa

Detalles Bibliográficos
Autores principales: Gulati, Nicholas, Celen, Arda, Johannet, Paul, Mehnert, Janice M., Weber, Jeffrey, Krogsgaard, Michelle, Osman, Iman, Zhong, Judy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559502/
https://www.ncbi.nlm.nih.gov/pubmed/34647433
http://dx.doi.org/10.1002/cam4.4239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559502/
https://www.ncbi.nlm.nih.gov/pubmed/34647433
http://dx.doi.org/10.1002/cam4.4239

Ejemplares similares